Facing the Challenges in Vaccine Upstream Bioprocessing - 34

Facing the Challenges in Vaccine Upstream Bioprocessing * Vero Perfusion, Packed-Bed Vessels Intensify Vaccine Production

rate on the last day (22.37 g), we obtained the
glucose-consumption-to-cell-density conversion
ratio at the end of the culture. Assuming that this
conversion ratio remained relatively unchanged
over the duration of the culture, we converted
the daily glucose consumption rate into daily cell
density. The calculated Vero cell growth curve is
shown in Figure 2B.

Conclusion
We have demonstrated that the Eppendorf
BioBLU 5p Single-Use Vessel prepacked with
Fibra-Cel disks is an excellent platform for highdensity Vero cell culture. In the 3.5-L vessel, we
achieved a high Vero cell density of approximately 43 million cells/mL, demonstrating great
potential for Vero cell-based vaccine production.
Since viral particles are much smaller than cells,
they can be directly eluted from packed-bed cell
culture vessels without removal of cells. In addition, as high Vero cell densities can be translated
into high virus production yield, that is, high titer,
the Fibra-Cel packed-bed platform is ideal for
high-titer viral vaccine production. n
34

| GENengnews.com

References
1. Milián E, Kamen AA. Current and Emerging Cell Culture
Manufacturing Technologies for Influenza Vaccines. Biomed.
Res. Int. 2015; 504831. doi: 10.1155/2015/504831. [Epub 2015
Mar 1.]
2. Han K, Sha M. High-Density Vero Cell Perfusion Culture in
BioBLU® 5p Single-Use Vessels. Eppendorf Application Note
359. October 2017.



http://www.GENengnews.com

Facing the Challenges in Vaccine Upstream Bioprocessing

Table of Contents for the Digital Edition of Facing the Challenges in Vaccine Upstream Bioprocessing

Contents
Facing the Challenges in Vaccine Upstream Bioprocessing - 1
Facing the Challenges in Vaccine Upstream Bioprocessing - 2
Facing the Challenges in Vaccine Upstream Bioprocessing - 3
Facing the Challenges in Vaccine Upstream Bioprocessing - Contents
Facing the Challenges in Vaccine Upstream Bioprocessing - 5
Facing the Challenges in Vaccine Upstream Bioprocessing - 6
Facing the Challenges in Vaccine Upstream Bioprocessing - 7
Facing the Challenges in Vaccine Upstream Bioprocessing - 8
Facing the Challenges in Vaccine Upstream Bioprocessing - 9
Facing the Challenges in Vaccine Upstream Bioprocessing - 10
Facing the Challenges in Vaccine Upstream Bioprocessing - 11
Facing the Challenges in Vaccine Upstream Bioprocessing - 12
Facing the Challenges in Vaccine Upstream Bioprocessing - 13
Facing the Challenges in Vaccine Upstream Bioprocessing - 14
Facing the Challenges in Vaccine Upstream Bioprocessing - 15
Facing the Challenges in Vaccine Upstream Bioprocessing - 16
Facing the Challenges in Vaccine Upstream Bioprocessing - 17
Facing the Challenges in Vaccine Upstream Bioprocessing - 18
Facing the Challenges in Vaccine Upstream Bioprocessing - 19
Facing the Challenges in Vaccine Upstream Bioprocessing - 20
Facing the Challenges in Vaccine Upstream Bioprocessing - 21
Facing the Challenges in Vaccine Upstream Bioprocessing - 22
Facing the Challenges in Vaccine Upstream Bioprocessing - 23
Facing the Challenges in Vaccine Upstream Bioprocessing - 24
Facing the Challenges in Vaccine Upstream Bioprocessing - 25
Facing the Challenges in Vaccine Upstream Bioprocessing - 26
Facing the Challenges in Vaccine Upstream Bioprocessing - 27
Facing the Challenges in Vaccine Upstream Bioprocessing - 28
Facing the Challenges in Vaccine Upstream Bioprocessing - 29
Facing the Challenges in Vaccine Upstream Bioprocessing - 30
Facing the Challenges in Vaccine Upstream Bioprocessing - 31
Facing the Challenges in Vaccine Upstream Bioprocessing - 32
Facing the Challenges in Vaccine Upstream Bioprocessing - 33
Facing the Challenges in Vaccine Upstream Bioprocessing - 34
Facing the Challenges in Vaccine Upstream Bioprocessing - 35
https://www.nxtbookmedia.com